Buy Recommendation for PDS Biotechnology Based on Promising Prostate Cancer Therapy
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor With an Immunocytokine
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and PDS Biotechnology (PDSB)
Noble Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $21
Express News | PDS Biotechnology Corp - Complete Metabolic Response Achieved in 88% of Patients